医药与保健
醫藥與保健
의약여보건
MEDICINE AND HEALTH CARE
2014年
4期
59-59,66
,共2页
米非司酮%安宫黄体酮%对比疗效
米非司酮%安宮黃體酮%對比療效
미비사동%안궁황체동%대비료효
Mifepristone%Medroxyprogesterone Acetate%Comparison of Clinical Effect
目的:讨论米非司酮与安宫黄体酮在临床上治疗围绝经期功血的效果。方法选取2011年3月至2013年8月在我院进行诊断性刮宫手术治疗的患者64例,将其随机分为实验组和对比组各32例,实验组使用米非司酮进行治疗,对比组使用安宫黄体酮进行治疗,比较两组患者在服药期间以及停止服药后子宫内膜厚薄度及性激素的改变。结果两组患者在服药后均获得一定疗效,但米非司酮有效率为93.75%明显高于安宫黄体酮68.75%的有效率(P<0.05);米非司酮在子宫内膜厚薄控制方面更优于安宫黄体酮(P<0.05)。结论米非司酮在治疗围绝经期功血方面的疗效明显优于安宫黄体酮的疗效,在临床上值得广泛推广。
目的:討論米非司酮與安宮黃體酮在臨床上治療圍絕經期功血的效果。方法選取2011年3月至2013年8月在我院進行診斷性颳宮手術治療的患者64例,將其隨機分為實驗組和對比組各32例,實驗組使用米非司酮進行治療,對比組使用安宮黃體酮進行治療,比較兩組患者在服藥期間以及停止服藥後子宮內膜厚薄度及性激素的改變。結果兩組患者在服藥後均穫得一定療效,但米非司酮有效率為93.75%明顯高于安宮黃體酮68.75%的有效率(P<0.05);米非司酮在子宮內膜厚薄控製方麵更優于安宮黃體酮(P<0.05)。結論米非司酮在治療圍絕經期功血方麵的療效明顯優于安宮黃體酮的療效,在臨床上值得廣汎推廣。
목적:토론미비사동여안궁황체동재림상상치료위절경기공혈적효과。방법선취2011년3월지2013년8월재아원진행진단성괄궁수술치료적환자64례,장기수궤분위실험조화대비조각32례,실험조사용미비사동진행치료,대비조사용안궁황체동진행치료,비교량조환자재복약기간이급정지복약후자궁내막후박도급성격소적개변。결과량조환자재복약후균획득일정료효,단미비사동유효솔위93.75%명현고우안궁황체동68.75%적유효솔(P<0.05);미비사동재자궁내막후박공제방면경우우안궁황체동(P<0.05)。결론미비사동재치료위절경기공혈방면적료효명현우우안궁황체동적료효,재림상상치득엄범추엄。
Objective To discuss the clinical effect of mifepristone and medroxyprogesterone acetate for treatment of perim enopausal uterine bleeding.Methods 64 patients received diagnostic curettage during March 2011 to August 2013 were chosen and randomly divided into experiment group and control group each with 32 cases.Experiment group was treated with mifepristone while control group was treated with medroxyprogesterone acetate.Endom etrialthickness and sex horm one changesduring medication and after medication of the 2 groups were com pared.Result After medication,both groups attained certain clinical effects, effective rate of mifepristone was 93.75%obviously higher than medroxyprogesterone acetate 68.75% (P<0.05);mifepristone was superior to medroxyprogesterone acetate on control of endom etrial thickness (P<0.05).Conclusion Mifepristone has a better clinical effect than medroxyprogesterone acetate on treating perim enopausaluterine bleeding and is worth of being popularized clinically.